GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TuHURA Biosciences Inc (NAS:HURA) » Definitions » EBITDA Margin %

HURA (TuHURA Biosciences) EBITDA Margin % : 0.00% (As of Dec. 2024)


View and export this data going back to 2024. Start your Free Trial

What is TuHURA Biosciences EBITDA Margin %?

EBITDA Margin % is calculated as EBITDA divided by its Revenue. TuHURA Biosciences's EBITDA for the three months ended in Dec. 2024 was $0.00 Mil. TuHURA Biosciences's Revenue for the three months ended in Dec. 2024 was $0.00 Mil. Therefore, TuHURA Biosciences's EBITDA margin for the quarter that ended in Dec. 2024 was 0.00%.


TuHURA Biosciences EBITDA Margin % Historical Data

The historical data trend for TuHURA Biosciences's EBITDA Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TuHURA Biosciences EBITDA Margin % Chart

TuHURA Biosciences Annual Data
Trend Dec21 Dec22 Dec23 Dec24
EBITDA Margin %
- - - -

TuHURA Biosciences Quarterly Data
Dec21 Mar22 Dec22 Mar23 Dec23 Mar24 Jun24 Sep24 Dec24
EBITDA Margin % Get a 7-Day Free Trial Premium Member Only - - - - -

Competitive Comparison of TuHURA Biosciences's EBITDA Margin %

For the Biotechnology subindustry, TuHURA Biosciences's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TuHURA Biosciences's EBITDA Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TuHURA Biosciences's EBITDA Margin % distribution charts can be found below:

* The bar in red indicates where TuHURA Biosciences's EBITDA Margin % falls into.


;
;

TuHURA Biosciences EBITDA Margin % Calculation

EBITDA margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent.

TuHURA Biosciences's EBITDA Margin % for the fiscal year that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (A: Dec. 2024 )/Revenue (A: Dec. 2024 )
=-17.427/0
= %

TuHURA Biosciences's EBITDA Margin % for the quarter that ended in Dec. 2024 is calculated as

EBITDA Margin %=EBITDA (Q: Dec. 2024 )/Revenue (Q: Dec. 2024 )
=0/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


TuHURA Biosciences  (NAS:HURA) EBITDA Margin % Explanation

EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.


TuHURA Biosciences EBITDA Margin % Related Terms

Thank you for viewing the detailed overview of TuHURA Biosciences's EBITDA Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


TuHURA Biosciences Business Description

Traded in Other Exchanges
N/A
Address
10500 University Center Drive, Suite 110, Tampa, FL, USA, 33612
TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.